2.7 Formulary Systems, Therapeutic Interchange & Medication Affordability
Key Takeaways
- Formulary systems guide product choice via tiers, prior authorization, step therapy, and institutional P&T decisions—outline 2A8 spans inpatient and outpatient contexts.
- Therapeutic interchange (different drug, similar class/effect) is not the same as generic substitution under B&P § 4073 and generally requires protocol or prescriber authorization.
- Insurance tiers and PA/step edits are administrative barriers pharmacists navigate with clinical alternatives—not automatic permission to switch molecules.
- Affordability tools (2A12) include formulary alternatives, patient assistance programs, manufacturer copay support when lawful, discount models, and 340B/clinic pathways when applicable.
- Resolving cost barriers must stay inside California substitution/interchange law: never silently substitute a non-equivalent drug to save money.
2.7 Formulary Systems, Therapeutic Interchange & Medication Affordability
Patients abandon therapy more often for cost than for taste. Outline tasks 2A8 (use a formulary system) and 2A12 (resolve medication affordability problems) test whether you can lower barriers without breaking California substitution law or clinical sense.
Formulary Systems (2A8)
A formulary is a continually revised list of preferred medications—and the policies that govern exceptions. Formularies appear in:
- Health-plan / PBM outpatient formularies (tiers, quantity limits, PA, step therapy).
- Hospital / health-system formularies managed by Pharmacy & Therapeutics (P&T) committees.
- Medicaid (Medi-Cal), Medicare Part D, and marketplace plan designs with distinct rules.
- Employer or integrated delivery network preferred-drug lists.
Tools inside a formulary system
| Tool | What it does | Pharmacist response pattern |
|---|---|---|
| Tiering | Higher patient cost share for non-preferred brands | Identify preferred alternative in class; discuss with patient/prescriber |
| Prior authorization (PA) | Plan requires documentation of medical necessity | Submit clinical rationale, labs, failure history; bridge therapy if allowed |
| Step therapy | Must try preferred agent first | Document prior use/intolerance; request exception when clinically inappropriate |
| Quantity / age limits | Restrict days supply or population | Clarify indication; request override |
| Therapeutic interchange protocols | Allow switch among formulary agents under policy | Follow written protocol; notify as required |
| Non-formulary / exclusion | Drug not covered | Propose covered alternative or medical exception |
P&T committees evaluate comparative efficacy, safety, and cost. On CPJE scenarios, supporting a formulary conversion means you can explain why the alternative is therapeutically appropriate for this patient (renal function, interactions, pregnancy, prior ADRs)—not merely that it is cheaper.
Generic Substitution vs Therapeutic Interchange
This distinction is a classic trap.
Generic substitution (same molecule, equivalent product)
Under B&P § 4073, when a prescription is written for a brand drug, a pharmacist may—and in many circumstances must—select a lower-cost generically equivalent product unless the prescriber or patient lawfully restricts substitution. Equivalence is guided by the FDA Orange Book (A-rated products). Biologics follow B&P § 4073.5 and Purple Book interchangeability rules, including prescriber notification when an interchangeable biologic is substituted.
Therapeutic interchange (different molecule)
Therapeutic interchange replaces one drug with a different chemical entity expected to have similar clinical effect (e.g., pantoprazole ↔ omeprazole; atorvastatin ↔ rosuvastatin under protocol). It is not authorized by § 4073 alone.
Lawful pathways typically include:
- Prescriber-authorized change on the order or after clarification.
- Institutional therapeutic interchange protocol approved through medical staff/P&T processes, with defined inclusions/exclusions.
- Collaborative practice / CDTM agreement empowering the pharmacist to select within a class.
- Plan-directed conversion programs only when the pharmacy’s participation and patient/prescriber notice rules are followed.
Silent community-pharmacy switching from prescribed drug A to non-equivalent drug B “because Tier 1 is cheaper” without authority is unlawful practice and a medication error, even if well-intentioned.
Advising patients and prescribers
Formulary counseling should cover: expected clinical similarity/differences, need for new titration or monitoring, cost estimate, and whether a PA or exception is wiser than a switch (e.g., stable seizure or transplant regimens). Document the conversation and the authority used for any interchange.
Insurance Tiers, PA, and Practical Navigation
When adjudication rejects a claim:
- Read the reject code (NDC not covered, PA required, step edit, refill too soon).
- Identify preferred alternatives on the plan formulary for the indication.
- Determine whether an exception request is clinically justified (contraindication to step agent, prior failure, drug–drug interaction).
- Communicate options: wait for PA, switch under authority, cash-pay short supply, or specialty pharmacy referral.
- Avoid abandoning the patient at the counter without a next step.
Specialty drugs often require limited networks, REMS, and benefits investigation. Affordability work then includes coordinating starter fills only when clinically and contractually appropriate.
Medication Affordability Strategies (2A12)
Affordability resolution is a clinical service, not charity improvisation.
Common tools
- Formulary-preferred therapeutic alternatives (with proper interchange authority).
- Generic or interchangeable biologic substitution under §§ 4073 / 4073.5.
- Patient Assistance Programs (PAPs) — manufacturer programs for uninsured/underinsured patients meeting income criteria; require applications and often prescriber signatures.
- Manufacturer copay cards / savings offers — generally for commercially insured patients; typically not valid for government beneficiaries (Medicare, Medicaid, TRICARE) under federal anti-kickback constraints—do not counsel Medicare patients to use banned copay cards.
- Nonprofit foundations and disease-specific grants for specialty cost shares.
- Pharmacy discount programs / cash pricing — compare to insurance copay; sometimes cash is lower (patient choice after counseling).
- Split billing / coordination with clinic 340B pathways when the patient is eligible through a covered entity—follow contract pharmacy rules; do not invent 340B eligibility.
- Tablet splitting only when the product is scored/suitable and clinically appropriate—never for CR/ER modified-release dosage forms that must remain intact.
- 90-day supplies / mail order when plan design lowers cost and adherence improves.
Ethical and legal guardrails
| Allowed | Not allowed |
|---|---|
| Substituting AB-rated generic per § 4073 | Dispensing a different drug entity without protocol/prescriber authority |
| Requesting PA with accurate clinical facts | Fabricating failure history to force approval |
| Helping enroll in PAP with truthful income docs | Using Medicare-prohibited manufacturer copay cards |
| Recommending OTC therapeutic options when appropriate | Omitting counseling on efficacy/safety differences |
Worked Scenario Pattern
Claim: Brand DPP-4 inhibitor rejected—non-formulary; preferred is another DPP-4 or SGLT2 depending on plan and comorbidities.
Process: Check A1C goal and eGFR; if SGLT2 preferred and indicated (CKD/HF benefit), recommend authorized interchange or new prescription; if patient must remain on specific DPP-4, start PA with documentation. Meanwhile assess cash price vs. PAP eligibility. Document patient preference, authority for any switch, and monitoring (e.g., genital infection counseling for SGLT2, volume status).
CPJE Take-Home
Formulary mastery is bilingual: speak Payer (tier, PA, step) and Law (equivalent substitution vs interchange authority). Affordability wins that violate § 4073/§ 4073.5 boundaries or therapeutic interchange limits are still failures. The successful California pharmacist lowers cost and preserves an authorized, clinically coherent regimen—with documentation that shows how the barrier was resolved.
A community pharmacist wants to save a patient money by dispensing pravastatin when the prescription clearly specifies atorvastatin 40 mg daily, without a therapeutic interchange protocol or prescriber approval. Which statement is correct?
Which affordability intervention is generally inappropriate to recommend for a Medicare Part D beneficiary needing help with a brand specialty drug copay?
A hospital P&T-approved therapeutic interchange protocol allows automatic conversion from IV esomeprazole to IV pantoprazole for most adult inpatients, with listed exclusions. What is the pharmacist’s best action for an eligible patient?
Adjudication returns “step therapy required—trial of preferred ARB before covering requested ARB.” The patient has documented angioedema from the preferred ARB. What is the most appropriate next step?